

Bonnie W Ramsey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1013005/publications.pdf>

Version: 2024-02-01

39
papers

12,726
citations

331670

21
h-index

315739

38
g-index

39
all docs

39
docs citations

39
times ranked

7047
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis. <i>New England Journal of Medicine</i> , 1994, 331, 637-642.	27.0	1,929
2	A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation. <i>New England Journal of Medicine</i> , 2011, 365, 1663-1672.	27.0	1,920
3	Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 918-951.	5.6	1,451
4	Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. <i>New England Journal of Medicine</i> , 2015, 373, 220-231.	27.0	1,308
5	Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. <i>New England Journal of Medicine</i> , 2019, 381, 1809-1819.	27.0	1,231
6	Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. <i>New England Journal of Medicine</i> , 1999, 340, 23-30.	27.0	1,226
7	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1940-1948.	13.7	804
8	Effect of VX-770 in Persons with Cystic Fibrosis and the <i>G551D</i> -CFTR Mutation. <i>New England Journal of Medicine</i> , 2010, 363, 1991-2003.	27.0	741
9	Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in <i>G551D</i> -mediated Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 175-184.	5.6	447
10	Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis*. <i>Pediatric Pulmonology</i> , 2001, 32, 356-366.	2.0	361
11	<i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Patients With <i>G551D</i> -CFTR Treated With Ivacaftor. <i>Clinical Infectious Diseases</i> , 2015, 60, 703-712.	5.8	198
12	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1522-1532.	5.6	146
13	Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , 1989, 7, 265-271.	2.0	142
14	Triple Therapy for Cystic Fibrosis <i>Phe508del</i> Gating and Residual Function Genotypes. <i>New England Journal of Medicine</i> , 2021, 385, 815-825.	27.0	140
15	Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 617-626.	10.7	129
16	Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1144-1151.	5.6	96
17	Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two <i>F508del</i> alleles. <i>ERJ Open Research</i> , 2019, 5, 00082-2019.	2.6	72
18	Future Directions in Early Cystic Fibrosis Lung Disease Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 887-892.	5.6	68

#	ARTICLE	IF	CITATIONS
19	Academic, Foundation, and Industry Collaboration in Finding New Therapies. <i>New England Journal of Medicine</i> , 2017, 376, 1762-1769.	27.0	57
20	Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors. <i>Pediatric Pulmonology</i> , 2015, 50, S3-S13.	2.0	56
21	Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 809-815.	0.7	50
22	<i>AJRCCM</i>: 100-Y<sc>ear</sc> A<sc>nniversary</sc>.Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1092-1099.	5.6	25
23	Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 657-663.	1.8	21
24	Serology as a diagnostic tool for predicting initial <i>Pseudomonas aeruginosa</i> acquisition in children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 542-549.	0.7	15
25	Update in Cystic Fibrosis 2018. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1188-1194.	5.6	13
26	Early attained weight and length predict growth faltering better than velocity measures in infants with CF. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 723-729.	0.7	12
27	Appropriate compensation of pediatric research participants: Thoughts from an Institute of Medicine committee report. <i>Journal of Pediatrics</i> , 2006, 149, S15-S19.	1.8	11
28	Use of Lung Imaging Studies as Outcome Measures for Development of New Therapies in Cystic Fibrosis. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 359-363.	3.5	9
29	Standardization of Researchâ€™Quality Anthropometric Measurement of Infants and Implementation in a Multicenter Study. <i>Clinical and Translational Science</i> , 2015, 8, 330-333.	3.1	9
30	Gastrointestinal Factors Associated With Hospitalization in Infants With Cystic Fibrosis: Results From the Baby Observational and Nutrition Study. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 73, 395-402.	1.8	7
31	Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2021, 20, e16-e18.	0.7	6
32	Impact of guideline-recommended dietitian assessments on weight gain in infants with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 115-122.	0.7	6
33	Caring for gender diverse youth with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 1018-1020.	0.7	5
34	Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new <i>Pseudomonas</i> . <i>Journal of Cystic Fibrosis</i> , 2022, 21, 946-949.	0.7	5
35	The Cystic Fibrosis Foundation Therapeutics Development Network: A National Effort by the Cystic Fibrosis Foundation to Build a Clinical Trials Network. <i>Children's Health Care</i> , 2008, 37, 5-20.	0.9	4
36	A new path for CF clinical trials through the use of historical controls. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 293-299.	0.7	3

#	ARTICLE	IF	CITATIONS
37	Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 487-489.	5.6	2
38	Comparative Monovalent Cation Transport in Neonatal and Adult Red Blood Cells. Pediatric Research, 1984, 18, 778-780.	2.3	1
39	Transparency and diversity in cystic fibrosis research – Authors' reply. Lancet, The, 2020, 396, 602.	13.7	0